ML355 is a selective inhibitor of 12-lipoxygenase (12-LOX), an enzyme involved in the metabolism of arachidonic acid. It is primarily used in research settings to study the role of 12-LOX in various biological processes and disease models. One key application is in the investigation of platelet function and thrombosis, as 12-LOX contributes to platelet activation and aggregation. By inhibiting this enzyme, ML355 helps researchers assess the potential of 12-LOX as a therapeutic target for preventing pathological clotting without impairing normal hemostasis. ML355 is also used in studies related to inflammation and oxidative stress, particularly in neurological and vascular tissues. It has shown utility in models of ischemic brain injury, where 12-LOX activity is linked to neuronal cell death. Additionally, it is being explored in diabetes research due to the enzyme’s involvement in beta-cell dysfunction and insulin resistance. Its selectivity makes it a valuable tool for dissecting signaling pathways without broad off-target effects on other lipoxygenase or cyclooxygenase enzymes. Overall, ML355 supports the development of targeted therapies for cardiovascular, metabolic, and neurodegenerative conditions.